Clinical Trial Details
— Status: Withdrawn
Administrative data
NCT number |
NCT02281981 |
Other study ID # |
Curcumin |
Secondary ID |
|
Status |
Withdrawn |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 2014 |
Est. completion date |
January 2016 |
Study information
Verified date |
June 2022 |
Source |
University of Prince Edward Island |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Arterial Stiffness: As a recognized independent indicator of cardiovascular risk, maintaining
low levels of arterial stiffening is important to cardiovascular health. Increases in
arterial stiffening results in elevated systolic and mean pressure and it is correlated with
various cardiovascular conditions such as left ventricular hypertrophy, ischaemic heart
disease, and myocardial infarction. In contrast, decreased arterial stiffness improves
ventricular-vascular coupling, ejection fraction, and cardiac output. Arterial stiffness is
linked to inflammation and oxidative stress. Both inflammation and oxidative stress are
elevated during DOMS (delayed onset muscle soreness), a state brought on by muscle damage
often incurred during strenuous exercise. Recent studies have shown that a single bout of
eccentric exercise can produce acute arterial stiffness during recovery. However,
anti-oxidants/anti-inflammatories may be effective in reducing the extent of damage by
decreasing oxidation and inflammation. Curcumin is a powerful antioxidant that could act as
an anti-inflammatory and diminish the effects of the downhill run. In addition, eccentric
damage generates a prophylactic protection lasting up to six weeks. The nature of the
downhill run is primarily eccentric in nature. Therefore, repeated bouts may have diminished
DOMS development. Any reduction in stress by either the prophylactic repeated bout effect or
the Curcumin supplement, should attenuate the increase in arterial stiffness due to the
reduction in inflammation.
Description:
Baseline Participants will report to the lab on day one to have basic anthropometry and
clinical measures performed. Following measures of height, weight, blood pressure, blood
lipids (fasting glucose), creatine kinase, high sensitivity C-reactive protein (HS-CRP) and
interleukin-6 (IL-6) participants will be allowed to eat a small standardized snack.
Participants will then have measures of baseline muscle soreness and leg strength measured
prior to a VO2max test on a cycle ergometer.
Muscle Soreness will be measured using a standard 10cm analogue scale and girth of the thigh
will be recorded to account for possible alterations owing to local inflammation/oedema./
Creatine Kinase (CK) will be tracked as a measure of damage.
The test termination criteria for the VO2max will include: volitional fatigue, a participant
rating of perceived exertion of 19-20 (on a scale from 0-20), a plateau in O2 uptake with
increasing workload, or and RER of >1.15. The VT of each participant will be noted to compare
with values post- training.
Testing Day 2 - This day will occur at least 1 full day (48h) following VO2max testing.
Participants will arrive at the lab having consumed a standardized breakfast. Prior to the
downhill run, measures of pulse wave velocity (PWV), heart rate variability (HRV), flow
mediated dilatation (FMD) will be collected according to the protocols to follow.
Participants will then perform a 40 minute downhill run at a grade of -12 percent using a
speed that elicits a VO2 of approximately 60% of the maximum value achieved during the max
test.
Arterial stiffness will be determined using a Sphygmocor CPVH pulse wave applanation
tonomoter (Atcor Medical). This device measures arterial pulse waves non-invasively through
the skin. By matching pulse wave arrival with heart beats (through a standard ECG tracing)
and measuring the distance between points we can calculate travel time (or velocity). We will
also use this same device to analyze the shape of the pulse wave, which will give us
information about reflected pulse waves (and thus the stiffness of the arterial tree).
Follow-up: At 24h, 48h, and 72h post exercise, participants will return to the lab to have
all of the non-exercise measures repeated (see figure 1). This will allow temporal tracking
over time.
Hypotheses:
1) The anti-inflammatory potential of Curcumin supplementation should improve post-exercise
recovery. 2) Repeated bouts of eccentrically biased downhill running should produce a
prophylactic effect and reduce arterial stiffness and recovery time